XML 75 R62.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Equity Instruments (Details 2) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2015 | Dec. 31, 2014 | Jun. 30, 2015 | Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Allocated Share-based Compensation Expense | $ 183,000 | $ 276,000 | $ 251,000 | $ 478,000 |  |
Unrecognized expense at December 31, 2015 | $ 1,890,000 |  |  |  |  |
Weighted average remaining years to vest (in years) | 3 years 1 month 28 days |  |  |  |  |
Luoxis Diagnostics [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Unrecognized expense at December 31, 2015 |  |  |  |  | $ 0 |
Weighted average remaining years to vest (in years) |  |  |  |  | 0 years |
Vyrix Pharmaceuticals Inc [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Unrecognized expense at December 31, 2015 |  |  |  |  | $ 0 |
Weighted average remaining years to vest (in years) |  |  |  |  | 0 years |
Stock Options [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Allocated Share-based Compensation Expense |  |  |  |  | $ 27,000 |
Research and Development Expense [Member] | Stock Options [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Allocated Share-based Compensation Expense | $ 20,000 | 117,000 | 25,000 | 207,000 |  |
Research and Development Expense [Member] | Stock Options [Member] | Luoxis Diagnostics [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Allocated Share-based Compensation Expense |  |  |  |  | 427,000 | $ 206,000
Research and Development Expense [Member] | Stock Options [Member] | Vyrix Pharmaceuticals Inc [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Allocated Share-based Compensation Expense |  |  |  |  | 92,000 | 38,000
General and Administrative Expense [Member] | Stock Options [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Allocated Share-based Compensation Expense | $ 163,000 | $ 159,000 | $ 226,000 | $ 271,000 | 1,018,000 | 500,000
General and Administrative Expense [Member] | Stock Options [Member] | Luoxis Diagnostics [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Allocated Share-based Compensation Expense |  |  |  |  | 316,000 | 152,000
General and Administrative Expense [Member] | Stock Options [Member] | Vyrix Pharmaceuticals Inc [Member] |  |  |  |  |  |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |  |  |  |  |  |
Allocated Share-based Compensation Expense |  |  |  |  | $ 183,000 | $ 104,000

X
- Definition Unrecognized share based compensation expenses. + References No definition available. + Details
Name: | aytu_UnrecognizedShareBasedCompensationExpenses
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.F) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section F + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=aytu_LuoxisDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=aytu_VyrixPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |